
Scotland has become the first part of the UK to approve a new treatment hailed as “cutting edge care” for patients with advanced stomach cancer.
The Scottish Medicines Consortium (SMC) has given the go-ahead for the drug zolbetuximab to be used, together with chemotherapy.